Anastrozole 1mg

DRUG8 trials

Conditions

Breast CancerBreast CarcinomaBreast Neoplasm FemaleCancer MetastaticER-positive Breast CancerErectile DysfunctionHER2-negative Breast CancerHormone Receptor Positive Tumor

Phase 2

Treatment of Sexual Dysfunction in Hypogonadal Men With Epilepsy With Testosterone and Either Anastrozole or Placebo

CompletedNCT00179517

Beth Israel Deaconess Medical CenterErectile Dysfunction, Hypogonadism, Seizure Disorder

Start: 2001-06-30End: 2008-04-30Updated: 2019-07-17

Aromatase Inhibitor and Durvalumab in Postmenopausal Breast Cancer

TerminatedNCT03874325

H. Lee Moffitt Cancer Center and Research InstituteBreast Cancer, Hormone Receptor Positive Tumor

Start: 2019-04-26End: 2021-01-06Updated: 2022-05-31

Anastrazole and Clomiphene to Evaluate Hypogonadal Symptoms and Erectile Function

CompletedNCT03933618

Albany Medical CollegeHypogonadism, Male

Start: 2015-04-02End: 2017-03-08Updated: 2019-11-18

Evaluation of ATRA Activity in Combination With Anastrozole in Pre-operative Phase of Operable Early Breast Cancer

TerminatedNCT04113863

Mario Negri Institute for Pharmacological ResearchBreast Neoplasm Female

Start: 2019-06-18End: 2025-01-30Updated: 2025-12-18

Neoadjuvant Endocrine Therapy in ER-positive, HER2-negative Early Stage Breast Cancer

Active, not recruitingNCT05150652

Irada Ibrahim-zadaBreast Cancer, Breast Carcinoma, HER2-negative Breast Cancer +1

Start: 2022-02-18End: 2026-06-09Updated: 2026-01-07

Phase 3

Endocrine Therapy With Abemaciclib or Chemotherapy as Initial Metastatic Treatment in ER+/HER2- Breast Cancer

Active, not recruitingNCT04158362

UNICANCERCancer Metastatic

Start: 2020-06-11End: 2028-06-30Updated: 2025-09-22

Elacestrant for Treating ER+/HER2- Breast Cancer Patients With ctDNA Relapse (TREAT ctDNA)

RecruitingNCT05512364

European Organisation for Research and Treatment of Cancer - EORTCER-positive Breast Cancer, HER2-negative Breast Cancer, Stage IIB Breast Cancer +1

Start: 2023-12-15End: 2035-11-01Target: 220Updated: 2025-08-19

Unknown Phase

Neoadjuvant Endocrine Therapy in Breast Cancer. Real Clinical Practice in Russia

NCT05800197

Blokhin's Russian Cancer Research CenterBreast Cancer, Neoadjuvant Endocrine Therapy

Start: 2014-04-15End: 2025-01-15Target: 300Updated: 2023-04-06

Related Papers

Abstract RF7-06: Primary results of Ambre, a randomized phase 3comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+/her2- advanced breast cancer (abc) with high visceral tumor burden

Clinical Cancer Research2026-02-17

Neoadjuvant therapy with an aromatase inhibitor and durvalumab in postmenopausal patients with hormone receptor-positive breast cancer.

2026-02-16

EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA).

Journal of Clinical Oncology2025-05-281 citations

heredERA Breast Cancer: a phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer

BMC Cancer2024-05-246 citations